Breast cancer risk reduction: Clinical Practice Guidelines in Oncology™

Therese B. Bevers, Deborah Kay Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Tom Lawton, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Victoria Seewaldt, Rena V. SellinCharles L. Shapiro, Eva Singletary, John H. Ward

Research output: Contribution to journalArticle

Abstract

Breast cancer risk assessment provides a means of identifying healthy women at increased risk for future development of this disease. However, many of the risk factors for breast cancer are not modifiable. The demonstration that use of tamoxifen or raloxifene for 5 years decreases the future risk for breast cancer by nearly 50% provides an opportunity for a risk reduction intervention. However, the risks and benefits associated with use of tamoxifen or raloxifene for an individual woman should be evaluated and discussed with patients as part of a shared decision-making process. Women taking a risk reduction agent must be closely monitored for potential side effects associated with use of these agents. In special circumstances, such as in carriers of a BRCA1/2 mutation, for whom the risk for breast cancer is very high, the performance of a bilateral mastectomy or bilateral salpingo-oophorectomy may be considered for breast cancer risk reduction. Women considering either surgery should undergo multidisciplinary consultations before surgery to become well informed about all treatment alternatives, the risks and benefits of risk reduction surgery, and, in the case of bilateral mastectomy, the various reconstruction options available. The panel strongly encourages women and health care providers to participate in clinical trials to test new strategies to decrease the risk for breast cancer. Only through the accumulated experience gained from prospective and well-designed clinical trials will additional advances in the reduction of breast cancer risk be realized.

Original languageEnglish (US)
Pages (from-to)676-701
Number of pages26
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number8
StatePublished - Sep 2007

Fingerprint

Risk Reduction Behavior
Practice Guidelines
Breast Neoplasms
Mastectomy
Tamoxifen
Clinical Trials
Ovariectomy
Women's Health
Health Personnel
Decision Making
Referral and Consultation
Mutation

Keywords

  • BCRA1
  • BCRA2
  • Breast carcinoma
  • LCIS
  • NCCN Clinical Practice Guidelines
  • Prophylactic mastectomy
  • Raloxifene
  • Risk assessment
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology

Cite this

Bevers, T. B., Armstrong, D. K., Arun, B., Carlson, R. W., Cowan, K. H., Daly, M. B., ... Ward, J. H. (2007). Breast cancer risk reduction: Clinical Practice Guidelines in Oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 5(8), 676-701.

Breast cancer risk reduction : Clinical Practice Guidelines in Oncology™. / Bevers, Therese B.; Armstrong, Deborah Kay; Arun, Banu; Carlson, Robert W.; Cowan, Kenneth H.; Daly, Mary B.; Fleming, Irvin; Garber, Judy E.; Gemignani, Mary; Gradishar, William J.; Krontiras, Helen; Kulkarni, Swati; Laronga, Christine; Lawton, Tom; Loftus, Loretta; MacDonald, Deborah J.; Mahoney, Martin C.; Merajver, Sofia D.; Seewaldt, Victoria; Sellin, Rena V.; Shapiro, Charles L.; Singletary, Eva; Ward, John H.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 5, No. 8, 09.2007, p. 676-701.

Research output: Contribution to journalArticle

Bevers, TB, Armstrong, DK, Arun, B, Carlson, RW, Cowan, KH, Daly, MB, Fleming, I, Garber, JE, Gemignani, M, Gradishar, WJ, Krontiras, H, Kulkarni, S, Laronga, C, Lawton, T, Loftus, L, MacDonald, DJ, Mahoney, MC, Merajver, SD, Seewaldt, V, Sellin, RV, Shapiro, CL, Singletary, E & Ward, JH 2007, 'Breast cancer risk reduction: Clinical Practice Guidelines in Oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 5, no. 8, pp. 676-701.
Bevers, Therese B. ; Armstrong, Deborah Kay ; Arun, Banu ; Carlson, Robert W. ; Cowan, Kenneth H. ; Daly, Mary B. ; Fleming, Irvin ; Garber, Judy E. ; Gemignani, Mary ; Gradishar, William J. ; Krontiras, Helen ; Kulkarni, Swati ; Laronga, Christine ; Lawton, Tom ; Loftus, Loretta ; MacDonald, Deborah J. ; Mahoney, Martin C. ; Merajver, Sofia D. ; Seewaldt, Victoria ; Sellin, Rena V. ; Shapiro, Charles L. ; Singletary, Eva ; Ward, John H. / Breast cancer risk reduction : Clinical Practice Guidelines in Oncology™. In: JNCCN Journal of the National Comprehensive Cancer Network. 2007 ; Vol. 5, No. 8. pp. 676-701.
@article{da41f91a05ea47768f23eefa39701cec,
title = "Breast cancer risk reduction: Clinical Practice Guidelines in Oncology™",
abstract = "Breast cancer risk assessment provides a means of identifying healthy women at increased risk for future development of this disease. However, many of the risk factors for breast cancer are not modifiable. The demonstration that use of tamoxifen or raloxifene for 5 years decreases the future risk for breast cancer by nearly 50{\%} provides an opportunity for a risk reduction intervention. However, the risks and benefits associated with use of tamoxifen or raloxifene for an individual woman should be evaluated and discussed with patients as part of a shared decision-making process. Women taking a risk reduction agent must be closely monitored for potential side effects associated with use of these agents. In special circumstances, such as in carriers of a BRCA1/2 mutation, for whom the risk for breast cancer is very high, the performance of a bilateral mastectomy or bilateral salpingo-oophorectomy may be considered for breast cancer risk reduction. Women considering either surgery should undergo multidisciplinary consultations before surgery to become well informed about all treatment alternatives, the risks and benefits of risk reduction surgery, and, in the case of bilateral mastectomy, the various reconstruction options available. The panel strongly encourages women and health care providers to participate in clinical trials to test new strategies to decrease the risk for breast cancer. Only through the accumulated experience gained from prospective and well-designed clinical trials will additional advances in the reduction of breast cancer risk be realized.",
keywords = "BCRA1, BCRA2, Breast carcinoma, LCIS, NCCN Clinical Practice Guidelines, Prophylactic mastectomy, Raloxifene, Risk assessment, Tamoxifen",
author = "Bevers, {Therese B.} and Armstrong, {Deborah Kay} and Banu Arun and Carlson, {Robert W.} and Cowan, {Kenneth H.} and Daly, {Mary B.} and Irvin Fleming and Garber, {Judy E.} and Mary Gemignani and Gradishar, {William J.} and Helen Krontiras and Swati Kulkarni and Christine Laronga and Tom Lawton and Loretta Loftus and MacDonald, {Deborah J.} and Mahoney, {Martin C.} and Merajver, {Sofia D.} and Victoria Seewaldt and Sellin, {Rena V.} and Shapiro, {Charles L.} and Eva Singletary and Ward, {John H.}",
year = "2007",
month = "9",
language = "English (US)",
volume = "5",
pages = "676--701",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "8",

}

TY - JOUR

T1 - Breast cancer risk reduction

T2 - Clinical Practice Guidelines in Oncology™

AU - Bevers, Therese B.

AU - Armstrong, Deborah Kay

AU - Arun, Banu

AU - Carlson, Robert W.

AU - Cowan, Kenneth H.

AU - Daly, Mary B.

AU - Fleming, Irvin

AU - Garber, Judy E.

AU - Gemignani, Mary

AU - Gradishar, William J.

AU - Krontiras, Helen

AU - Kulkarni, Swati

AU - Laronga, Christine

AU - Lawton, Tom

AU - Loftus, Loretta

AU - MacDonald, Deborah J.

AU - Mahoney, Martin C.

AU - Merajver, Sofia D.

AU - Seewaldt, Victoria

AU - Sellin, Rena V.

AU - Shapiro, Charles L.

AU - Singletary, Eva

AU - Ward, John H.

PY - 2007/9

Y1 - 2007/9

N2 - Breast cancer risk assessment provides a means of identifying healthy women at increased risk for future development of this disease. However, many of the risk factors for breast cancer are not modifiable. The demonstration that use of tamoxifen or raloxifene for 5 years decreases the future risk for breast cancer by nearly 50% provides an opportunity for a risk reduction intervention. However, the risks and benefits associated with use of tamoxifen or raloxifene for an individual woman should be evaluated and discussed with patients as part of a shared decision-making process. Women taking a risk reduction agent must be closely monitored for potential side effects associated with use of these agents. In special circumstances, such as in carriers of a BRCA1/2 mutation, for whom the risk for breast cancer is very high, the performance of a bilateral mastectomy or bilateral salpingo-oophorectomy may be considered for breast cancer risk reduction. Women considering either surgery should undergo multidisciplinary consultations before surgery to become well informed about all treatment alternatives, the risks and benefits of risk reduction surgery, and, in the case of bilateral mastectomy, the various reconstruction options available. The panel strongly encourages women and health care providers to participate in clinical trials to test new strategies to decrease the risk for breast cancer. Only through the accumulated experience gained from prospective and well-designed clinical trials will additional advances in the reduction of breast cancer risk be realized.

AB - Breast cancer risk assessment provides a means of identifying healthy women at increased risk for future development of this disease. However, many of the risk factors for breast cancer are not modifiable. The demonstration that use of tamoxifen or raloxifene for 5 years decreases the future risk for breast cancer by nearly 50% provides an opportunity for a risk reduction intervention. However, the risks and benefits associated with use of tamoxifen or raloxifene for an individual woman should be evaluated and discussed with patients as part of a shared decision-making process. Women taking a risk reduction agent must be closely monitored for potential side effects associated with use of these agents. In special circumstances, such as in carriers of a BRCA1/2 mutation, for whom the risk for breast cancer is very high, the performance of a bilateral mastectomy or bilateral salpingo-oophorectomy may be considered for breast cancer risk reduction. Women considering either surgery should undergo multidisciplinary consultations before surgery to become well informed about all treatment alternatives, the risks and benefits of risk reduction surgery, and, in the case of bilateral mastectomy, the various reconstruction options available. The panel strongly encourages women and health care providers to participate in clinical trials to test new strategies to decrease the risk for breast cancer. Only through the accumulated experience gained from prospective and well-designed clinical trials will additional advances in the reduction of breast cancer risk be realized.

KW - BCRA1

KW - BCRA2

KW - Breast carcinoma

KW - LCIS

KW - NCCN Clinical Practice Guidelines

KW - Prophylactic mastectomy

KW - Raloxifene

KW - Risk assessment

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=34848897217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848897217&partnerID=8YFLogxK

M3 - Article

C2 - 17927926

AN - SCOPUS:34848897217

VL - 5

SP - 676

EP - 701

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 8

ER -